Daraxonrasib
Pharmaceutical compound
Nº Q136659312 ★★★★
Super rara · Saberes
Daraxonrasib
Pharmaceutical compound
Daraxonrasib, sold under the brand name Rasonque, is an anti-cancer medication used for the treatment of pancreatic cancer. It is an inhibitor of the RAS GTPase family. It is an orally administered small molecule pan-RAS inhibitor.
Último preço
—
Preço mínimo
—
Mediana 7 d
—
Vendas 30 d
0
Faixa 30 d
—
Em circulação
0
Cotação
mediana
mín – máx
vendas
Sem vendas no período
Ver tabela
| Data | mediana | Mín | Máx | vendas |
|---|
Histórico de vendas
- Última venda
- —
- Média 30 d
- —
- Mínima 30 d
- —
- Máxima 30 d
- —
- Vendas 7 d
- 0
- Vendas 30 d
- 0
Ainda sem vendas.
Vendas anônimas: sem comprador nem vendedor. Os números contam só vendas entre jogadores.
Na Wikipédia
Texto em inglês Ainda não há artigo no seu idioma: trecho em inglês.
Daraxonrasib, sold under the brand name Rasonque, is an anti-cancer medication used for the treatment of pancreatic cancer. It is an inhibitor of the RAS GTPase family. It is an orally administered small molecule pan-RAS inhibitor. It was developed by Revolution Medicines. It inhibits all three key members of the Ras superfamily: KRAS, HRAS, and NRAS. The three RAS proteins are GTPases that become active when bound to GTP but normally convert this GTP to GDP and thereby become inactive. RAS proteins that are bound to GDP and GTP are termed respectively RAS(OFF) and RAS(ON). Daraxonrasib targets RAS in the ON state, but not in the OFF state. Daraxonrasib was approved for medical use in the United States in August 2026.
Texto: Wikipédia em inglês, CC BY-SA 4.0. · Imagem: Vaccinationist (Public domain) ·
